Deutsche Bank AG purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 106,049 shares of the company's stock, valued at approximately $12,161,000. Deutsche Bank AG owned approximately 0.13% of Kymera Therapeutics as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in KYMR. GAMMA Investing LLC increased its position in shares of Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after buying an additional 98 shares in the last quarter. US Bancorp DE lifted its holdings in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company's stock worth $106,000 after acquiring an additional 166 shares in the last quarter. Glenmede Trust Co. NA grew its stake in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company's stock valued at $565,000 after acquiring an additional 235 shares during the period. Cetera Investment Advisers grew its stake in Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company's stock valued at $300,000 after acquiring an additional 252 shares during the period. Finally, Larson Financial Group LLC increased its holdings in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company's stock worth $83,000 after acquiring an additional 287 shares in the last quarter.
Insider Buying and Selling
In other news, Director Bruce Booth sold 31,283 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84. Following the sale, the director directly owned 461,794 shares in the company, valued at $50,557,207.12. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Noah Goodman sold 3,389 shares of the business's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the sale, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,604,813 shares of company stock valued at $387,557,004 over the last ninety days. Insiders own 15.98% of the company's stock.
Kymera Therapeutics Stock Performance
NASDAQ:KYMR opened at $119.80 on Friday. The company has a market cap of $9.96 billion, a PE ratio of -36.98 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52-week low of $39.84 and a 52-week high of $130.05. The stock has a 50-day simple moving average of $109.42 and a 200 day simple moving average of $92.03.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million for the quarter, compared to analysts' expectations of $32.78 million. During the same quarter in the previous year, the business posted ($0.95) EPS. The business's quarterly revenue was up 465.2% compared to the same quarter last year. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on KYMR. B. Riley Financial raised their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a "buy" rating in a research report on Monday, June 29th. Truist Financial boosted their price objective on Kymera Therapeutics from $116.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Guggenheim increased their target price on Kymera Therapeutics from $125.00 to $135.00 and gave the stock a "buy" rating in a research note on Tuesday, July 28th. Oppenheimer restated an "outperform" rating and set a $125.00 target price on shares of Kymera Therapeutics in a report on Wednesday, August 5th. Finally, Barclays raised their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Twenty equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $125.65.
Get Our Latest Stock Analysis on KYMR
Kymera Therapeutics Profile
(
Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Read More
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
